Last reviewed · How we verify
NCT06066957
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
Phase 2 trial testing Letermovir 480 MG [Prevymis] in Cytomegalovirus Infections in 80 participants. Currently enrolling.
15 August 2026
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 4 April 2024 |
| Primary completion | 15 August 2026 |
| Estimated completion | 15 August 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Letermovir 480 MG [Prevymis] — full drug profile →
Conditions studied
- Cytomegalovirus Infections — all drugs for Cytomegalovirus Infections →
- Transplant-Related Disorder — all drugs for Transplant-Related Disorder →
Sponsor
University of Pennsylvania
Who can join
18 and older, any sex, with Cytomegalovirus Infections or Transplant-Related Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Open label study to determine tolerability and efficacy of letermovir for CMV prophylaxis in heart and lung transplant recipients. The study hypotheses are: 1. Letermovir prophylaxis will be associated with similar rates of CMV infection as valganciclovir among heart and lung transplant recipients 2. Letermovir will be better tolerated than valganciclovir for CMV prophylaxis in heart and lung transplant recipients, with a higher proportion of days of completed therapy with correct dosing during the planned prophylaxis period 3. Letermovir will have a lower rate of neutropenia than valganciclovir when used for CMV prophylaxis in heart and lung transplant recipients 4. Incorrect renal dosing will occur less frequently with letermovir than with valganciclovir when used for CMV prophylaxis in heart and lung transplant recipients
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir.
Piret J, Boivin G. · · 2024 · cited 14× · PMID 38247977 · DOI 10.3390/idr16010005 -
Letermovir should be first-line cytomegalovirus prophylaxis in lung transplant recipients.
Mezochow AK, Clausen E, Whitaker K, Claridge T, et al · · 2025 · cited 7× · PMID 39884651 · DOI 10.1016/j.ajt.2025.01.038 -
Cytomegalovirus infections in thoracic organ transplant recipients: Updates on prevention, treatment, and immune monitoring.
Collis BJ, Heldman MR, Wolfe CR. · · 2026 · PMID 41695191 · DOI 10.1016/j.jhlto.2025.100449
Verify or expand the search:
- PubMed search for NCT06066957
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cytomegalovirus Infections
Currently open trials in the same condition.
- NCT07013370 — Immunoglobiulin-specific Prophylaxis of Citomegalovirus Infections in Immunocompromised Children Undergoing Allogeneic H · recruiting
- NCT06909110 — Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With · Phase 1, PHASE2 · recruiting
- NCT06694428 — Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CMV) Infecti · recruiting
- NCT06812598 — Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogenei · NA · recruiting
- NCT06554197 — Evaluation of CMV/EBV-CMI in Haploid HSCT · recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06066957 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 21 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06066957.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing